Associations between

tumor response measures, pCR and SUV, and covariates were tested using the Fisher Exact Test. A 0.05 nominal significance level was used in all hypothesis testing. All statistical analyses were performed using SAS, version 9.3, statistical software (SAS Institute Inc., Cary, NC). Results A total of 18 consecutive patients who received trimodality therapy between July 2010 and October 2011 were evaluated. Two patients were excluded who received chemotherapy and/or radiation therapy at an outside institution despite undergoing operative intervention at our institution. The remaining 16 patients Inhibitors,research,lifescience,medical received all aspects of their care at our institution. Patient and tumor characteristics Patient and tumor characteristics are Inhibitors,research,lifescience,medical summarized in Table 1. All patients were Caucasian males with a median age of 60 years and ECOG performance status (PS) of 0-1. Tobacco use was common among our patient population with 82% of patients reporting current or past history of usage. Table 1 Patient and tumor characteristics All patients had moderately to poorly differentiated adenocarcinomas. Inhibitors,research,lifescience,medical Three patients had signet ring features and one was found to have mucin production. Over half

of the esophageal tumors were considered AEG 1 as defined by the Siewert classification with the tumor epicenter located between 1-5 cm above the GEJ (12). The average length of the tumor was 4.4 cm (1-9 cm). EUS was performed in 38% of patients for staging. All patients underwent pretreatment PET/CT revealing a mean SUV of 9.7 [0-21]. Utilizing the American Joint Committee on Cancer AJCC seventh addition, Inhibitors,research,lifescience,medical most patients were stage IIA/B or IIIA. All patients were at least a clinical/radiographic T2 or with clinically/radiographically positive nodes which was documented in 6 patients. Treatment characteristics All patients Inhibitors,research,lifescience,medical received conformal radiation to 50.4 Gy using a VMAT technique with concurrent carboplatin and paclitaxel, with a mean of

6 cycles. Treatment parameters are summarized in Table 2. Median elapsed time from diagnosis to completion of concurrent chemoradiaton was 76 days (44-141 days), from diagnosis to surgery was 143 days (99-224 days), and from completion of concurrent chemoradiation to surgery was 66 days (35-92 days). Four patients did require a break from treatment ABT-263 mw secondary to fever/bronchitis, body rash, thrombocytopenia, and an unspecified reason. Dichloromethane dehalogenase Table 2 Chemoradiotherapy Pathologic and SUV response Pathologic and SUV response to neoadjuvant therapy was reviewed (Table 3). All patients received R0 resections. The mean number of lymph nodes harvested was 19 [7-39]. pCR was achieved in 6 (38%) patients with an additional 5 (31%) patients having only minimal residual disease. The remaining 5 patients (31%) had macroscopic residual disease. One patient had pathologic nodal disease seen at resection.